A four-drug standardized short regimen for highly resistant TB in South-West Nigeria

Muse O Fadeyi; Tom Decroo; Nimer Ortuño-Gutiérrez; Bolaji Ahmed; Aderonke Jinadu; Osman El-Tayeb; Wasiu Adebola; Aderemi Kehinde; Lutgarde Lynen; Tinne Gils

doi:10.1093/inthealth/ihad023

A four-drug standardized short regimen for highly resistant TB in South-West Nigeria

Muse O Fadeyi, Tom Decroo, Nimer Ortuño-Gutiérrez, Bolaji Ahmed, Aderonke Jinadu, Osman El-Tayeb, Wasiu Adebola, Aderemi Kehinde, Lutgarde Lynen, Tinne Gils

Research output: Contribution to journal › A1: Web of Science-article › peer-review

34 Downloads (Pure)

Abstract

Background: Patients with TB resistant to rifampicin (Rr-TB), and those with additional resistance to fluoroquinolones (pre-XDR-TB), should be treated with bedaquiline-pretomanid-linezolid-moxifloxacin and bedaquiline-pretomanid-linezolid, respectively. However, pretomanid is not yet widely available.

Methods: This is a pragmatic prospective single-arm study investigating the efficacy and safety of 9 mo of bedaquiline-delamanid-linezolid-clofazimine in patients with pre-XDR-TB or Rr-TB unresponsive to Rr-TB treatment in Nigeria.

Results: From January 2020 to June 2022, 14 of 20 patients (70%) successfully completed treatment, five died and one was lost-to-follow-up. No one experienced a treatment-emergent grade three/four event. Treatment success was higher compared with global pre-XDR-TB treatment outcomes.

Conclusions: While pretomanid is unavailable, highly resistant TB can be treated with bedaquiline-delamanid-linezolid-clofazimine.

Original language	English
Article number	ihad023
Journal	International Health
ISSN	1876-3413
DOIs	https://doi.org/10.1093/inthealth/ihad023
Publication status	E-pub ahead of print - 2023

Access to Document

10.1093/inthealth/ihad023Licence: CC BY-NC

2023iheaihad023Final published version, 178 KBLicence: CC BY-NC

Cite this

@article{f55f47bc1dc740b7b62c388281cd1c7a,

title = "A four-drug standardized short regimen for highly resistant TB in South-West Nigeria",

abstract = "Background: Patients with TB resistant to rifampicin (Rr-TB), and those with additional resistance to fluoroquinolones (pre-XDR-TB), should be treated with bedaquiline-pretomanid-linezolid-moxifloxacin and bedaquiline-pretomanid-linezolid, respectively. However, pretomanid is not yet widely available.Methods: This is a pragmatic prospective single-arm study investigating the efficacy and safety of 9 mo of bedaquiline-delamanid-linezolid-clofazimine in patients with pre-XDR-TB or Rr-TB unresponsive to Rr-TB treatment in Nigeria.Results: From January 2020 to June 2022, 14 of 20 patients (70%) successfully completed treatment, five died and one was lost-to-follow-up. No one experienced a treatment-emergent grade three/four event. Treatment success was higher compared with global pre-XDR-TB treatment outcomes.Conclusions: While pretomanid is unavailable, highly resistant TB can be treated with bedaquiline-delamanid-linezolid-clofazimine.",

author = "Fadeyi, {Muse O} and Tom Decroo and Nimer Ortu{\~n}o-Guti{\'e}rrez and Bolaji Ahmed and Aderonke Jinadu and Osman El-Tayeb and Wasiu Adebola and Aderemi Kehinde and Lutgarde Lynen and Tinne Gils",

note = "FTX; (CC BY-NC 4.0); {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.",

year = "2023",

doi = "10.1093/inthealth/ihad023",

language = "English",

journal = "International Health",

issn = "1876-3413",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - A four-drug standardized short regimen for highly resistant TB in South-West Nigeria

AU - Fadeyi, Muse O

AU - Decroo, Tom

AU - Ortuño-Gutiérrez, Nimer

AU - Ahmed, Bolaji

AU - Jinadu, Aderonke

AU - El-Tayeb, Osman

AU - Adebola, Wasiu

AU - Kehinde, Aderemi

AU - Lynen, Lutgarde

AU - Gils, Tinne

N1 - FTX; (CC BY-NC 4.0); © The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

PY - 2023

Y1 - 2023

N2 - Background: Patients with TB resistant to rifampicin (Rr-TB), and those with additional resistance to fluoroquinolones (pre-XDR-TB), should be treated with bedaquiline-pretomanid-linezolid-moxifloxacin and bedaquiline-pretomanid-linezolid, respectively. However, pretomanid is not yet widely available.Methods: This is a pragmatic prospective single-arm study investigating the efficacy and safety of 9 mo of bedaquiline-delamanid-linezolid-clofazimine in patients with pre-XDR-TB or Rr-TB unresponsive to Rr-TB treatment in Nigeria.Results: From January 2020 to June 2022, 14 of 20 patients (70%) successfully completed treatment, five died and one was lost-to-follow-up. No one experienced a treatment-emergent grade three/four event. Treatment success was higher compared with global pre-XDR-TB treatment outcomes.Conclusions: While pretomanid is unavailable, highly resistant TB can be treated with bedaquiline-delamanid-linezolid-clofazimine.

AB - Background: Patients with TB resistant to rifampicin (Rr-TB), and those with additional resistance to fluoroquinolones (pre-XDR-TB), should be treated with bedaquiline-pretomanid-linezolid-moxifloxacin and bedaquiline-pretomanid-linezolid, respectively. However, pretomanid is not yet widely available.Methods: This is a pragmatic prospective single-arm study investigating the efficacy and safety of 9 mo of bedaquiline-delamanid-linezolid-clofazimine in patients with pre-XDR-TB or Rr-TB unresponsive to Rr-TB treatment in Nigeria.Results: From January 2020 to June 2022, 14 of 20 patients (70%) successfully completed treatment, five died and one was lost-to-follow-up. No one experienced a treatment-emergent grade three/four event. Treatment success was higher compared with global pre-XDR-TB treatment outcomes.Conclusions: While pretomanid is unavailable, highly resistant TB can be treated with bedaquiline-delamanid-linezolid-clofazimine.

U2 - 10.1093/inthealth/ihad023

DO - 10.1093/inthealth/ihad023

M3 - A1: Web of Science-article

C2 - 37026448

SN - 1876-3413

JO - International Health

JF - International Health

M1 - ihad023

ER -

A four-drug standardized short regimen for highly resistant TB in South-West Nigeria

Abstract

Access to Document

Fingerprint

Cite this